The beautiful metropolis, Shanghai will provide a perfect setting for the Annual Congress of International Drug Discovery Science & Technology. IDDST initiated since 2003, it has been successfully hosted in Shanghai (China), Beijing (China), Shenzhen (China), Nanjing (China), Haikou (China), Suzhou (China), Xi’an (China), Gyeonggi (South Korea), Osaka (Japan), Boston (USA) and Kyoto (Japan) and has attracted more than 10000 participants from over 50 countries and regions in the previous years. IDDST will keep expanding with magnificent scientific and social programs to maximize your network in a free communication meeting environment.
● Inviting Worldwide Distinguished Experts in the Area of Drug Discovery for the Grand Thought
● Collision from more than 30 Countries Designing over 50 Sessions of Scientific Forums and Symposia
● Shooting for more than 200 Oral Presentations in whole Spectrum of Drug Discovery Fields
● Gathering at least 30 Exhibitors in Cutting-edge Technologies and Novel Bioproducts
● Bringing in 20 and more Professional Media Supporters
● Scheduling 5 Sessions of Business & Career Development, and Talent Search
● Multi-Zones of Poster Show and Exhibitions of New Finding, New IP, New Tech and Products
|
Chapter 1: Opening Ceremony and Keynote Forum |
|
|
Chapter 2: Parallel Forums |
|
|
Forum 1: Early Drug Discovery |
|
|
Track 1: Target Identification and Validation |
Track 2: Hit Identification and Optimization |
|
Track 3: Lead Generation and Optimization |
Track 4: Active Pharmaceutical Ingredients |
|
Forum 2: Preclinical Research |
|
|
Track 5: Chemical Manufacture and Control |
Track 6: Pharmacokinetics/ Pharmacodynamics |
|
Track 7: Drug Safety Evaluation |
Track 8: Formulation Optimization & Improving Bioavailability |
|
Forum 3: Investigational New Drug Application |
|
|
Track 9: IND-enabling Studies |
Track 10: IND Application |
|
Forum 4: Clinical Research |
|
|
Track 11: Phase I Clinical Trials |
Track 12: Phase II Clinical Trials |
|
Track 13: Phase III Clinical Trials |
— |
|
Forum 5: Regulatory Approval and Post Approval |
|
|
Track 14: New Drug Application |
Track 15: Post-Approval Research & Monitoring |
|
Chapter 3: Posters and Exhibition |
|
|
Chapter 4: Social Activities and Cultural Events |
|
|
|
Dr. Anil K. Agarwal, Associate Professor, Northwestern University, USA
|
|
Dr. Mark Bradley, Chair and Centre Lead, Queen Mary University of London, UK
|
|
Dr. Renfeng Guo, CSO, Inflarx Pharmaceutical Inc., USA |
|
|
Dr. Jens Erik Nielsen, Vice President, Enzyme Research, Novozymes A/S, Denmark |
|
Dr. Thomas Wittlinger, Professor, Goslar Hospital, Germany |
|
Dr. Muxiang Zhou, Professor, Emory University School of Medicine, USA |
|
|
Dr. Frank Yu Wang, Professor of Chemistry, University of North Carolina, USA |
|
Dr. Da Zhi Liu, Professor, University of California at Davis; Founder, Mirnova Therapeutics, Inc., USA |
|
Dr. Guang Sun, Professor, Memorial University of Newfoundland, Canada |
|
|
Dr. Horacio N. Pappa, Senior Director, United States Pharmacopeia, USA |
|
Dr. Franklin Wong, Professor, The University of Texas M. D. Anderson Cancer Center, USA |
|
Dr. Michael Castagna, Chief Executive Officer, MannKind Corporation, USA |
|
|
Dr. Jasmina Novakovic, Principal Scientist, Simulations Plus, Inc., USA |
|
Dr. Bernat Kocsis, Associate Professor, Beth Israel Deaconess Medical Center, USA |
|
Dr. Chuanxi Cai, Associate Professor, Albany Medical College, USA |
|
|
Dr. Maliha Zahid, Associate Professor, Mayo Clinic, USA |
|
Dr. Aneta Nitsch-Osuch, Professor, Medical University of Warsaw, Poland |
|
Dr. Alexander Tuzikov, Professor, National Academy of Sciences of Belarus, Belarus |
|
|
Dr. Xiaojian Yao, Director, Laboratory of Molecular Human Retrovirology, University of Manitoba, Canada |
